LeonaBio (LONA) CSO exercises 5,856 RSUs and sells shares for taxes

Rhea-AI Filing Summary

LeonaBio, Inc. Chief Scientific Officer Kevin Church reported RSU vesting and related share transactions. On March 3, he exercised 5,856 restricted stock units, each converting into one share of common stock at a stated price of $0.00 per share.

Those RSUs, originally granted as 5,856 units on March 3, 2025 and vesting in full one year later, increased his common stock holdings. On March 4, 1,359 common shares were sold in open-market transactions at a weighted-average price of $5.37 per share solely to cover tax withholding obligations under LeonaBio’s mandatory “sell to cover” policy.

After these transactions, Church directly held 25,178 shares of LeonaBio common stock.

Insider Trade Summary

Net Seller: 1,359 shares ($7,298)

Net Sell 3 txns

Insider CHURCH KEVIN

Role CHIEF SCIENTIFIC OFFICER

Sold 1,359 shs ($7K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,359	$5.37	$7K
Exercise	Restricted Stock Units	5,856	$0.00	--
Exercise	Common Stock	5,856	$0.00	--

Holdings After Transaction: Common Stock — 25,178 shares (Direct); Restricted Stock Units — 0 shares (Direct)

Footnotes (1)

1. Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the Issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $5.03 to $5.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Each RSU represents a contingent right to receive one (1) share of Issuer's common stock. On March 3, 2025, the reporting person was granted 5,856 RSUs (as adjusted for the 10-for-1 reverse stock split completed on September 17, 2025). 100% of the RSUs vested on the one (1) year anniversary of the grant date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CHURCH KEVIN

(Last) (First) (Middle)

C/O LEONABIO, INC.

18706 NORTH CREEK PARKWAY, SUITE 104

(Street)

BOTHELL WA 98011

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LeonaBio, Inc. [ LONA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF SCIENTIFIC OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		M		5,856	A	$0	26,537	D
Common Stock	03/04/2026		S(1)		1,359	D	$5.37(2)	25,178	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(3)	03/03/2026		M			5,856	(4)	(4)	Common Stock	5,856	$0	0	D

Explanation of Responses:

1. Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the Issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person.

2. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $5.03 to $5.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

3. Each RSU represents a contingent right to receive one (1) share of Issuer's common stock.

4. On March 3, 2025, the reporting person was granted 5,856 RSUs (as adjusted for the 10-for-1 reverse stock split completed on September 17, 2025). 100% of the RSUs vested on the one (1) year anniversary of the grant date.

	/s/ Mark Worthington, Attorney-in-Fact on behalf of Kevin Church	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did LeonaBio (LONA) report for Kevin Church?

LeonaBio reported that Chief Scientific Officer Kevin Church exercised 5,856 restricted stock units into common shares, then sold 1,359 common shares. The sale occurred at a weighted-average price of $5.37 and was done to cover tax withholding obligations under a mandatory company policy.

How many LeonaBio (LONA) shares does Kevin Church hold after these transactions?

After the reported transactions, Kevin Church directly holds 25,178 shares of LeonaBio common stock. This reflects the conversion of 5,856 restricted stock units into shares and the subsequent tax-related sale of 1,359 shares under the company’s mandatory “sell to cover” policy.

Were Kevin Church’s LeonaBio (LONA) share sales discretionary?

The sale of 1,359 LeonaBio common shares by Kevin Church was not discretionary. Footnotes explain the shares were sold solely to cover tax withholding and remittance obligations triggered by RSU vesting, under a mandatory “sell to cover” policy and the applicable RSU agreement terms.

At what price were Kevin Church’s LeonaBio (LONA) shares sold?

The 1,359 LeonaBio common shares sold for a weighted-average price of $5.37 per share. Footnotes note these were multiple trades executed between $5.03 and $5.70, and the reporting person will provide detailed breakdowns upon request to the company, shareholders, or SEC staff.

What are the terms of Kevin Church’s vested LeonaBio (LONA) RSUs?

Each restricted stock unit represents the right to receive one share of LeonaBio common stock. Church was granted 5,856 RSUs on March 3, 2025, adjusted for a 10-for-1 reverse stock split, and 100% of those units vested on the one-year anniversary of the grant date.

How do Kevin Church’s RSU exercises affect LeonaBio (LONA) common stock?

When Kevin Church exercised 5,856 restricted stock units, they converted into an equal number of LeonaBio common shares at a stated price of $0.00. This increased his direct share ownership, before accounting for the subsequent 1,359-share sale to satisfy tax withholding obligations.